Tachykinin production by carcinoid tumours in culture
- PMID: 3477459
- DOI: 10.1016/0277-5379(87)90264-1
Tachykinin production by carcinoid tumours in culture
Abstract
Tissue specimens from 5 patients with metastatic midgut carcinoid tumours were kept in organ culture for up to 6 months. The tumour cells were confined to the suspension in the form of condensed cell clusters and appeared to retain their endocrine characteristics. Radioimmunoassay for tachykinin immunoreactivity showed high concentrations in 4 out of 5 culture media. The concentrations were highest in the beginning of the experiment, but subsequently decreased. The 4 patients from which these tumours were taken had all elevated tachykinin concentrations in extracted plasma. The fifth culture medium had low tachykinin concentration, and the concentration in extracted plasma from this patient was within the normal range. Reversed-phase high-performance liquid chromatography of the culture media with elevated tachykinin concentrations revealed immunoreactive components with the characteristics of synthetic neuropeptide K, neurokinin A and eledoisin, components also found in plasma and tumour tissues of carcinoid patients. Our findings indicate that carcinoid tumour cells produce tachykinins. These peptides are biologically very active, resulting in flush and hypotension when infused intravenously into normals, and might contribute to the clinical symptoms of the carcinoid syndrome.
Similar articles
-
Immunoreactive tachykinins in 24-h collections of urine from patients with carcinoid tumours: characterization and correlation with plasma concentrations.Scand J Clin Lab Invest. 1995 Dec;55(8):679-89. doi: 10.3109/00365519509075398. Scand J Clin Lab Invest. 1995. PMID: 8903838
-
Neuropeptide K: a major tachykinin in plasma and tumor tissues from carcinoid patients.Biochem Biophys Res Commun. 1985 Aug 30;131(1):77-83. doi: 10.1016/0006-291x(85)91772-3. Biochem Biophys Res Commun. 1985. PMID: 2412557
-
Increased intestinal non-substance P tachykinin concentrations in malignant midgut carcinoid disease.J Gastroenterol Hepatol. 1999 May;14(5):500-7. doi: 10.1046/j.1440-1746.1999.01888.x. J Gastroenterol Hepatol. 1999. PMID: 10355517
-
The biological hallmarks of ileal carcinoids.Eur J Clin Invest. 2011 Dec;41(12):1353-60. doi: 10.1111/j.1365-2362.2011.02537.x. Epub 2011 May 23. Eur J Clin Invest. 2011. PMID: 21605115 Review.
-
Carcinoids and carcinoid syndrome.Am J Med. 1987 May 29;82(5B):4-16. doi: 10.1016/0002-9343(87)90422-0. Am J Med. 1987. PMID: 2884878 Review. No abstract available.
Cited by
-
What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators.Endocr Rev. 2024 May 7;45(3):351-360. doi: 10.1210/endrev/bnad035. Endocr Rev. 2024. PMID: 38038364 Free PMC article.
-
Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.Gut. 2006 Nov;55(11):1586-91. doi: 10.1136/gut.2006.092320. Epub 2006 Mar 23. Gut. 2006. PMID: 16556667 Free PMC article.
-
Peptidergic Systems and Cancer: Focus on Tachykinin and Calcitonin/Calcitonin Gene-Related Peptide Families.Cancers (Basel). 2023 Mar 9;15(6):1694. doi: 10.3390/cancers15061694. Cancers (Basel). 2023. PMID: 36980580 Free PMC article. Review.
-
The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells.Br J Cancer. 1991 Jul;64(1):23-8. doi: 10.1038/bjc.1991.233. Br J Cancer. 1991. PMID: 1713051 Free PMC article.
-
Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms.PLoS One. 2017 Dec 12;12(12):e0188876. doi: 10.1371/journal.pone.0188876. eCollection 2017. PLoS One. 2017. PMID: 29232390 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical